1 The EIC Accelerator Project

The EIC Accelerator program, part of the European Innovation Council (EIC), is a pivotal funding initiative designed to support innovative small and medium-sized enterprises (SMEs) and startups across Europe. This program aims to stimulate the development and deployment of breakthrough technologies, particularly in the DeepTech sector, by providing financial support through a blend of grants and equity investments.

Overview of Funding Structure

The EIC Accelerator offers funding in two main forms: grants and equity investments.

Purpose of the EIC Accelerator

The EIC Accelerator serves a crucial role in the European startup and DeepTech ecosystem by reducing the financial burden on innovative companies during the early stages of development. It facilitates access to critical funding that can be challenging to secure through traditional venture capital routes, particularly for high-risk projects that require substantial investment in research and development. By supporting these companies, the EIC Accelerator aims to foster innovation, create jobs, and enhance Europe’s competitive edge in the global market.

Role in Scaling and Funding

The EIC Accelerator not only provides financial support but also plays a strategic role in helping companies scale their operations. By offering a combination of grants and equity, it enables startups to leverage public funding to attract further investments from private sectors. This blended finance approach is particularly beneficial for companies with high growth potential, allowing them to validate their business models and technology before pursuing additional funding rounds.

Case Study: LATTICE MEDICAL and the MATTISSE Project

Company Overview: LATTICE MEDICAL, based in France, is an innovative company focused on advancing the field of breast reconstruction. Its flagship project, MATTISSE, was chosen for funding under the EIC Accelerator program.

Project Description: The MATTISSE project aims to revolutionize breast reconstruction through the use of patients' own tissue. This self-reconstruction technique is designed to offer more natural and effective outcomes for breast cancer survivors, addressing the limitations of traditional reconstruction methods that often rely on implants.

Technology Basics and Background: The MATTISSE project employs a unique approach to tissue engineering. It utilizes a lightweight, bio-integrative scaffold that encourages tissue regeneration and growth, allowing for a more organic reconstruction process. The technology is based on advanced materials that promote the integration of the patient’s own tissue, minimizing the risk of rejection and complications associated with synthetic implants.

The innovative nature of the MATTISSE project lies not only in its technical execution but also in the potential to improve the quality of life for breast cancer survivors. By enabling self-reconstruction, LATTICE MEDICAL addresses crucial aspects of patient autonomy and body image, offering a solution that resonates deeply with the emotional and physical needs of patients.

Conclusion

The EIC Accelerator program represents a significant investment in Europe’s innovation landscape, particularly for high-impact projects like LATTICE MEDICAL’s MATTISSE. By providing a blend of grant and equity funding, the program empowers startups to navigate the challenges of bringing groundbreaking technologies to market, ultimately contributing to advancements in healthcare and enhancing patient outcomes. As the program continues to evolve, it remains a vital resource for fostering innovation and scaling impactful solutions across Europe. For more information about LATTICE MEDICAL and its transformative work, visit lattice-medical.com.

2 The Funding Rounds

LATTICE MEDICAL: Funding and Financing Overview Since EIC Accelerator Success (France)

Company: Lattice Medical
Country: France
EIC Accelerator Cut-off Date (Step 2 Submission): October 6, 2021

---

Financing Raised & Funding Rounds

Second Fundraising Round – €8 Million (2023):

In 2023, Lattice Medical completed a significant fundraising round of €8 million. This round coincided with the initiation of clinical trials for their flagship MATTISSE breast reconstruction implant. The company highlighted this milestone as a pivotal point in advancing its research and development pipeline.

France 2030 Grant – €6 Million (January 2024):

On January 17, 2024, Lattice Medical announced it secured €6 million in funding under the France 2030 investment plan’s i-Demo call for projects. This grant supports the multi-year LIPOTEC project focused on expanding therapeutic indications for the MATTISSE device through European clinical trials and developing digital twin technology to personalize surgical planning and manufacturing.

---

Timing and Amount of Funding Rounds

Date	Amount	Type	Purpose/Notes
Late-2023	€8M	Equity Round	Second major fundraising; start of MATTISSE clinical trials
January 17, ’24	€6M	Non-dilutive/Grant	France2030/i-Demo support for R&D (LIPOTEC)

</em>The €6M is described as funding from French public innovation programs rather than traditional venture or equity rounds.

---

Investor Information

Lattice Medical credits several long-term financial partners with supporting its growth journey but does not publicly disclose specific investor names on its main website or PR materials post-EIC Accelerator success. However:

• The company acknowledges close collaboration with institutional innovation backers such as BPIFrance, SGPI (Secrétariat Général Pour l’Investissement), Agence Innovation Santé, ONCOLille, INSERM CANTHER U1277 laboratory, and participation via FrenchTech initiatives.
• Their EIC Fund process was described by CEO Julien Payen as an opportunity to build a roadmap alongside lead investors brought in during their Series A efforts after winning EIC backing in late-2021/early-2022.

No non-public data regarding private VC or angel investors has been disclosed since their EIC win.

---

Company Valuation

Dealroom.co estimates that by October 2022—after securing major public/private funding—Lattice Medical’s enterprise value was between $35–53 million USD. No newer valuation figures are available publicly following subsequent financing rounds or grant awards. There is no record of unicorn status or valuations approaching nine digits.

---

Exit Events: IPOs / Buyouts / Acquisitions

As of April 23, 2025:

• There are no reported IPOs.
• No buyouts or acquisition events have taken place.

The company remains private and independent since receiving EIC Accelerator support.

---

Summary Table: Major Post-EIC Funding Events

Year	Month	Event Type	Amount
~Q4 '23	Late '23	Equity Round	€8M
Jan '24	Jan ’24	Public Grant/Funding	€6M

</em>From France2030/i-Demo program; supports R&D rather than direct equity dilution.

---

Notes on Growth Milestones Linked to Funding

Recent funds have enabled: - Clinical trial expansion for MATTISSE implant,

• Preparation for CE marking,
• Planned US FDA clinical investigations,
• Development of digital twin/surgical planning tech,

and long-term ambitions to target up to five percent market share in the global breast reconstruction field by decade’s end.

No exit event has yet occurred; further late-stage financing may be required before considering options such as IPO.

---

Sources

• Investors - Lattice Medical
• LATTICE MEDICAL secures 6 million euros in funding
• LATTICE MEDICAL company information & funding — Dealroom.co
• European Innovation Council Portfolio: LATTICE MEDICAL

3 The Press Releases

Overview of Lattice Medical

Lattice Medical, a French medical device company, specializes in developing innovative solutions for breast reconstruction. Their flagship product, the MATTISSE device, is a resorbable bioprosthesis designed for patients undergoing breast reconstruction after total mastectomy. This device facilitates the regeneration of autologous adipose tissue, offering a less invasive alternative to traditional reconstruction methods.

Recent Developments and Partnerships

• TIDE Clinical Trial: Lattice Medical has initiated the TIDE clinical trial in France, focusing on the safety and performance of the MATTISSE device. The trial is conducted in multiple centers, including Lille University Hospital and Strasbourg University Hospitals, with additional sites opening in Paris at Institut Gustave Roussy and Tenon Hospital AP-HP.
• 3D Printing Innovations: Lattice Medical has collaborated with 3devo to enhance the production of bioabsorbable filaments for their 3D-printed implants. This partnership has improved operational efficiency and allowed for precise control over filament quality, crucial for the MATTISSE implant.
• Presence at MedInTechs: Lattice Services, a branch of Lattice Medical, participated in the MedInTechs exhibition in Paris, showcasing their filaments and services related to 3D printing in the medical sector.

Technology Advancements

Lattice Medical's technology focuses on using a bioabsorbable 3D scaffold combined with autologous fat for breast reconstruction. This approach aims to simplify the reconstruction process while reducing long-term risks associated with permanent implants. The MATTISSE device is designed to resorb over time, allowing for natural tissue regeneration and minimizing the need for additional surgeries.

Press Releases and Updates

Recent updates from Lattice Medical include the expansion of their TIDE clinical trial to multiple sites in France. Interested patients can contact participating hospitals for more information. Additionally, Lattice Medical has been promoting their work through events like MedInTechs, highlighting their innovative materials and services for medical 3D printing.

Sources

• Lattice Medical: Opening of the TIDE study at the Strasbourg CHRU
• TIDE clinical trial opens in France
• MedInTechs 2023
• Lattice Medical 3D Tech: Innovative Breast Reconstruction

4 The Technology Advancements

Current Capabilities of Lattice Medical

Lattice Medical, a French company founded in 2017, specializes in tissue engineering, biomaterials, and 3D printing, focusing on developing innovative implants for reconstructive surgery. The company is particularly known for its MATTISSE device, a fully degradable, 3D printed breast implant designed for natural breast reconstruction after mastectomies. This technology enables the regeneration of autologous adipose tissue, offering a more natural and simplified approach to breast reconstruction compared to traditional methods.

Advancements Since EIC Accelerator Funding

Following the EIC Accelerator funding in late 2021, Lattice Medical has made significant advancements in its technology and market presence. The funding supported the commercialization of the MATTISSE technology, facilitating clinical trials for CE marking and initiating the process for FDA certification in the U.S.. Key developments include:

• Clinical Trials: Lattice Medical has progressed with clinical trials for the MATTISSE implant. The TIDE clinical trial, announced in September 2023, marked the opening of the First-In-Human (FIH) interventional study in France, following similar approvals in Georgia in 2022. These trials aim to evaluate the safety and performance of the MATTISSE device, including fat tissue regeneration and patient quality of life.
• Awards and Recognition: The company has received notable recognition, including the FrenchTech 2030 award in June 2023 and nomination for the Prix Galien 2023 in July. Additionally, Lattice Medical secured €6 million in funding under the France 2030 plan in January 2024. In December 2024, it won the Mid-Stage Grand Prize at the MedTech Innovator competition, acknowledging its innovative approach to breast reconstruction.
• Technological Improvements: The company continues to refine its technology, leveraging advancements in 3D printing and biomaterials to enhance the efficiency and accuracy of its implant production. This includes using high-precision filament makers to optimize material usage and reduce costs.

Market and Clinical Demonstrations

Lattice Medical has demonstrated its technology through clinical trials, specifically with the TIDE study in France. The company's focus on natural, resorbable implants has positioned it for potential market leadership in human soft tissue repair, aiming to replace silicone implants and improve accessibility for patients requiring breast reconstruction.

New Patents, Studies, and Trials

While specific details on new patents are not readily available, Lattice Medical's ongoing clinical trials and technological development indicate continuous innovation. The company's commitment to advancing its MATTISSE technology involves ongoing research and potential future publications related to its clinical results and technological improvements. There is ongoing communication regarding its clinical trials and plans for further market expansion, including potential clinical investigations in the U.S..

Future Plans

Lattice Medical is planning to finalize its clinical trials, pursue CE marking, and start FDA certification processes. The company aims to launch clinical investigations in the U.S. and expand its product offerings, such as the RODIN project, to further establish itself in the reconstructive surgery market.

Sources

• About us - Lattice Medical - Tissue engineering
• TIDE clinical trial opens in France - Lattice Medical
• Lattice Medical company information, funding & investors
• Revolutionizing Tissue Reconstruction with 3D-Printing Technology
• MedTech Innovator's 2024 winners - Today's Medical Developments
• LATTICE MEDICAL awarded by the EIC Accelerator
• Investors - Lattice Medical

5 The Partnerships and Customers

LATTICE MEDICAL, a French company specializing in tissue engineering and biomaterials for breast reconstruction, has developed a patented bio-resorbable implant technology called MATTISSE. Since receiving EIC Accelerator funding around October 2021, the company has advanced several strategic partnerships and customer relationships that are positioning it strongly in the market and supporting its technology development and scaling ambitions.

Partnerships and Customers

• Cousin Biotech: LATTICE MEDICAL established a partnership with Cousin Biotech to install a 3D printing farm within a clean room environment dedicated to producing medical devices. This collaboration is critical for scaling up production capabilities of their medical grade 3D printing filaments used for implants.
• Clinical Partnerships: The company has conducted clinical trials on MATTISSE implants involving patients (notably an initial study on 10 patients), progressing towards CE marking in Europe and preparing for FDA approval via clinical investigations in the USA. These clinical partnerships with hospitals or surgical centers facilitate validation of safety, performance data, and regulatory compliance essential to market entry.
• Digital Platform Collaborations: LATTICE MEDICAL is developing an integrated digital platform that supports surgeons with customized implant design through advanced 3D modeling tools such as Solidworks, Catia (for product design), Simulia (for biomechanical simulation), and Delmia (for production scale-up). This platform also offers preoperative visualization aiding surgical decision-making. The use of Dassault Systèmes’ 3DEXPERIENCE platform integrates these technologies into one collaborative environment enhancing innovation capability.

Recent Developments on New Relationships

No publicly disclosed new customers or partners beyond those mentioned above were identified specifically tied to post-EIC funding activities; however:

• The ongoing clinical investigations both in Europe and the USA represent expanding collaborations with healthcare providers aiming at regulatory approvals.
• The relationship with Cousin Biotech notably enhances manufacturing capacity by enabling scalable production infrastructure essential for commercialization.

Market Positioning Through Relationships

These relationships position LATTICE MEDICAL as an innovator advancing autologous breast reconstruction beyond current silicone implants towards safer, personalized tissue-engineered solutions. Clinical trial partnerships underpin credibility necessary for regulatory approval while manufacturing alliances support industrial-scale deployment—both vital to capturing part of the €900 million addressable market across key regions including Europe, US, Brazil where demand is growing annually.

The digital platform collaboration further distinguishes Lattice by combining innovative implant technology with cutting-edge digital tools that improve surgical outcomes through customization—a competitive advantage likely strengthening its leadership claims in human soft tissue repair markets.

Impact on Technology Advancement & Scaling

Partnerships have significantly contributed to: - Accelerating product development cycles via integrated simulation/design software.

• Enabling scale-up from research prototypes to manufacturable medical devices through cleanroom-grade additive manufacturing capacity.
• Supporting international regulatory strategy via multi-center clinical trials.

Together these enable Lattice Medical not only to refine its innovative MATTISSE implants but also prepare robust commercial operations capable of meeting anticipated demand growth targeting helping about 40,000 women by 2030.

---

Sources:

• Investors - Lattice Medical
• Tissue engineering & biomaterials - About us | Lattice Medical
• LATTICE MEDICAL | Dassault Systèmes® - 3DEXPERIENCE Lab
• Tissue engineering & filament production - Lattice Services

6 The Hiring and Company Growth

Lattice Medical: Team Growth and Strategic Hiring Post-EIC Accelerator Funding

Since winning EIC Accelerator funding (submission October 2021), Lattice Medical has expanded its team to support clinical trials, regulatory milestones, and production scaling. The company’s headcount grew to 25 engineers, PhDs, and specialists by late 2023–2024, up from 12 employees in 2020. Key developments include:

• Recent hiring focus: Roles span R&D, production, quality management, and business development. Positions listed as of 2024 include Biomechanics Engineers, Regulatory Affairs Managers, and Business Developers.
• Growth drivers:
• Clinical trials for MATTISSE (breast reconstruction implant) launched at Lille and Strasbourg University Hospitals.
• Expansion of its 3D printing farm for medical-grade implants under ISO 13485 certification.
• Strategic impact of new hires: Expertise in biomaterials and industrial processes supports scaling production capacity for MATTISSE while advancing RODIN (skin regeneration) pipeline.
• Management continuity: CEO Julien Payen remains founder/leader alongside original co-founders (plastic surgeons/biochemists), with no major leadership changes reported post-funding.

The company actively recruits specialists in biomedical engineering and regulatory compliance to meet EU/US commercialization targets, reflecting a push toward global market entry post-clinical validation.

---

Sources

• Interview with Julien Payen: Lattice Medical
• About us - Lattice Medical
• Careers - Lattice Medical
• Tissue engineering filament history

7 The Media Features and Publications

Overview of Lattice Medical

Lattice Medical is a French start-up specializing in tissue engineering and 3D printing for soft tissue regeneration. Founded in 2017, the company has developed innovative medical devices, including the MATTISSE, a bio-resorbable breast implant, and RODIN, a matrix for regenerating the hypodermis. Since receiving the EIC Accelerator funding in October 2021, Lattice Medical has been actively involved in advancing its technology and participating in various events.

Media Features and Publications

Lattice Medical has been featured in several publications highlighting its breakthrough technology in breast reconstruction. A notable article in The Engineer discusses how the company's 3D-printed breast implant promises to transform lives of breast cancer patients. Additionally, Lattice Medical publishes scientific studies, including in vitro and pre-clinical studies, which are reported in various scientific journals.

Content from Publications

Publications about Lattice Medical focus on its innovative approach to reconstructive surgery using biomaterials and 3D printing. The company's MATTISSE device is designed to facilitate natural, customized breast reconstruction, addressing a significant need in the field where only 20% of women who undergo mastectomy receive breast reconstruction.

Podcasts and Interviews

Julien Payen has represented Lattice Medical in various presentations, such as the LSI USA '24 Emerging Medtech Summit, where he discussed the company's expertise in tissue engineering and 3D printing.

Conference and Fair Visits

Lattice Medical has participated in significant events, including the LSI USA '24 Emerging Medtech Summit. Additionally, the company is likely to engage with similar future events, such as the LSI Europe '24 in Portugal.

Involvement in Events

The company's involvement in events highlights its commitment to advancing medical technology and engaging with the broader healthcare community. Lattice Medical's participation in conferences and summits helps in showcasing its innovative solutions and building partnerships in the medical technology sector.

Sources

• Lattice Medical Scientific Publications
• mattisse - Lattice Medical
• 3D Printing A Breast Reconstruction Revolution
• LATTICE MEDICAL | Dassault Systèmes - 3DEXPERIENCE Lab
• Julien Payen, Lattice Medical - Implants for Soft Tissue Regeneration